Enzalutamide reduced TMPRSS2 expression by inhibiting AR activity in LNCaP and VCaP cells, and significantly inhibited infection of these prostate cells by both authentic SARS-CoV-2 or SARS-CoV-2-S pseudovirus. Here, AR is linked to infection.